Carsten Pelz1, Sonja Häckel1,2, Geo Semini1,3, Sandra Schrötter1,4, Willem Bintig1, Sebastian Stricker1, Gudrun Mrawietz1, Andreas Klein1, Lothar Lucka1, Vadim Shmanai5, Britta Eickholt1, Annette Hildmann1,6, Kerstin Danker7. 1. Institut für Biochemie, Charité - Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, D-10117, Berlin, Germany. 2. AO Research Institute Davos, Clavadelerstr. 8, 7270, Davos-Platz, Switzerland. 3. Robert Koch-Institut Berlin, Seestrasse 10, 13353, Berlin, Germany. 4. Department of Genetics and Complex Diseases, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA, 02115, USA. 5. Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus, Surganova st. 13, 220072, Minsk, Belarus. 6. Octapharma Biopharmaceuticals GmbH, Walther-Nernst-Straße 3, 12489, Berlin, Germany. 7. Institut für Biochemie, Charité - Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, D-10117, Berlin, Germany. kerstin.danker@charite.de.
Abstract
PURPOSE: Previous studies have identified alkyl-phospholipids as promising compounds for cancer therapy by targeting constituents of the cell membrane and different signaling pathways. We previously showed that the alkylphospholipid Inositol-C2-PAF inhibits the proliferation and migration of immortalized keratinocytes and the squamous carcinoma-derived cell line SCC-25. Here, we investigated the effect of this compound on growth and motility as well as its mode of action in mammary carcinoma-derived cell lines. METHODS: Using BrdU incorporation and haptotactic cell migration assays, we assessed the effects of Inositol-C2-PAF on MCF-7 and MBA-MB-231 cell proliferation and migration. The phosphorylation status of signaling molecules was investigated by Western blotting as well as indirect immunofluorescence analysis and capillary isoelectric focusing. RESULTS: We found that Inositol-C2-PAF inhibited the growth as well as the migration in MCF-7 and MBA-MB-231 cells. Furthermore, we found that this compound inhibited phosphorylation of the protein kinase Akt at serine residue 473, but had no impact on phosphorylation at threonine 308. Phosphorylation of other kinases, such as Erk1/2, FAK and Src, which are targeted by Inositol-C2-PAF in other cells, remained unaffected by the compound in the mammary carcinoma-derived cell lines tested. In MCF-7 cells, we found that IGF-1-induced growth, as well as phosphorylation of AktS473, mTOR and the tumor suppressor pRB, was inhibited in the presence of Inositol-C2-PAF. Moreover, we found that in these cells IGF-1 had no impact on migration and did not seem to be linked to full Akt activity. Therefore, MCF-7 cell migration appears to be inhibited by Ino-C2-PAF in an Akt-independent manner. CONCLUSION: The antagonistic effects of Inositol-C2-PAF on cell migration and proliferation are indicative for its potential for breast cancer therapy, alone or in combination with other cytostatic drugs.
PURPOSE: Previous studies have identified alkyl-phospholipids as promising compounds for cancer therapy by targeting constituents of the cell membrane and different signaling pathways. We previously showed that the alkylphospholipidInositol-C2-PAF inhibits the proliferation and migration of immortalized keratinocytes and the squamous carcinoma-derived cell line SCC-25. Here, we investigated the effect of this compound on growth and motility as well as its mode of action in mammary carcinoma-derived cell lines. METHODS: Using BrdU incorporation and haptotactic cell migration assays, we assessed the effects of Inositol-C2-PAF on MCF-7 and MBA-MB-231 cell proliferation and migration. The phosphorylation status of signaling molecules was investigated by Western blotting as well as indirect immunofluorescence analysis and capillary isoelectric focusing. RESULTS: We found that Inositol-C2-PAF inhibited the growth as well as the migration in MCF-7 and MBA-MB-231 cells. Furthermore, we found that this compound inhibited phosphorylation of the protein kinase Akt at serine residue 473, but had no impact on phosphorylation at threonine 308. Phosphorylation of other kinases, such as Erk1/2, FAK and Src, which are targeted by Inositol-C2-PAF in other cells, remained unaffected by the compound in the mammary carcinoma-derived cell lines tested. In MCF-7 cells, we found that IGF-1-induced growth, as well as phosphorylation of AktS473, mTOR and the tumor suppressor pRB, was inhibited in the presence of Inositol-C2-PAF. Moreover, we found that in these cells IGF-1 had no impact on migration and did not seem to be linked to full Akt activity. Therefore, MCF-7 cell migration appears to be inhibited by Ino-C2-PAF in an Akt-independent manner. CONCLUSION: The antagonistic effects of Inositol-C2-PAF on cell migration and proliferation are indicative for its potential for breast cancer therapy, alone or in combination with other cytostatic drugs.
Authors: Clarissa von Haefen; Jana Wendt; Geo Semini; Marco Sifringer; Claus Belka; Silke Radetzki; Werner Reutter; Peter T Daniel; Kerstin Danker Journal: Apoptosis Date: 2011-06 Impact factor: 4.677
Authors: Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal Journal: Curr Cancer Drug Targets Date: 2008-05 Impact factor: 3.428
Authors: María Ángela Aznar; Beatriz Lasa-Saracíbar; Ander Estella-Hermoso de Mendoza; María José Blanco-Prieto Journal: Int J Pharm Date: 2013-04-30 Impact factor: 5.875